Systematic review of infectious events with the BTK inhibitor ibrutinib in the treatment of haematologic malignancies
ConclusionsIbrutinib use requires prudent consideration of the impacts on host immunity. We identified a high rate of serious adverse infectious events within prospective clinical trials. Data suggest a role of both BTK and ITK inhibition for the increased events. There was considerable variability in the reporting of adverse events between trials, journals, and conference reports.This article is protected by copyright. All rights reserved.
Source: European Journal of Haematology - Category: Hematology Authors: Benjamin F. Tillman, James M. Pauff, Gowri Satyanarayana, Mahsa Talbott, Jeremy L. Warner Tags: Review Article Source Type: research